Amgen (XTER:AMG) Ending Cash Position : €11,434 Mil (As of Dec. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Amgen Ending Cash Position?

Amgen's Ending Cash Position for the quarter that ended in Dec. 2024 was €11,434 Mil.

Amgen's quarterly Ending Cash Position declined from Jun. 2024 (€8,641 Mil) to Sep. 2024 (€8,119 Mil) but then increased from Sep. 2024 (€8,119 Mil) to Dec. 2024 (€11,434 Mil).

Amgen's annual Ending Cash Position increased from Dec. 2022 (€7,202 Mil) to Dec. 2023 (€10,036 Mil) and increased from Dec. 2023 (€10,036 Mil) to Dec. 2024 (€11,434 Mil).

Amgen Ending Cash Position Historical Data

The historical data trend for Amgen's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Ending Cash Position Chart

Amgen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

5,150.65

7,070.27

7,201.78

10,035.65

11,434.22

Amgen Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															10,035.65	8,931.36	8,640.63	8,118.91	11,434.22

Amgen Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Amgen's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	10451.52	+	982.695
	=	11,434

Amgen's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	8605.505	+	2828.71
	=	11,434

Amgen Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Amgen's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (XTER:AMG) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico 1AMGN:Italy AMGd:UK 0R0T:UK AMG:Germany AMG:Germany AMG:Germany AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.